tirzepatide trials Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in clinical practice EASD 2023: meta-analysis shows tirzepatide

evaluated the U.S

Semaglutide use has also become widespread among individuals without the clinical characteristics indicated in the marketing authorization, eager to lose weight more easily and efficiently, and further encouraged to use semaglutide off-label by social media and celebrities (Suran, 2023)

Y.MarshallL

It is the first oral GLP-1 medication approved specifically for weight management

In the first phase, the mice were randomly placed into the water from one of the four quadrants each day to search for an underwater escape platform, and the time taken by the mice to swim to and find the platform served as the escape latency period